WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
V09IX19vidoflufolastat (18F)Final2026
V09GX06flurpiridaz (18F)01.09.20252026
V08CA13gadoquatrane01.09.20252026
V04CX13pegulicianineFinal2026
V04CH05relmapirazin01.09.20252026
V04CF02mycobacterium tuberculosis, recombinant antigens01.09.20252026
S01BA17clobetasolFinal2026
S01AX26cethexonium01.09.20252026
R03DX12depemokimabFinal2026
R03BX02ensifentrineFinal2026
P02CA53albendazole and ivermectinFinal2026
N07XX27levacetylleucine01.09.20252026
N07XX26pridopidineFinal2026
N06DX07hydromethylthionineFinal2026
N06DX06blarcamesineFinal2026
N06DA06benzgalantamineFinal2026
N06BX53piracetam and cinnarizineFinal2026
N05CD16dimdazenil01.09.20252026
N05AX50xanomeline and trospium01.09.20252026
M09AX16apitegromab01.09.20252026
M04AB06dotinurad01.09.20252026
L04AX11monomethyl fumarate01.09.20252026
L04AL03nipocalimabFinal2026
L04AG19axatilimabFinal2026
L04AG18sibeprenlimabFinal2026
L04AF09deuruxolitinibFinal2026
L04AC27cendakimabFinal2026
L04AA62tolebrutinib01.09.20252026
L04AA61nerandomilastFinal2026
L03AX25thymalfasin01.09.20252026
L03AC03nogapendekin alfa and inbakiceptFinal2026
L02BA05camizestrant01.09.20252026
L01XX87revumenib01.09.20252026
L01XK07senaparib01.09.20252026
L01FX39bemarituzumab01.09.20252026
L01FX38ifinatamab deruxtecan01.09.20252026
L01FX37linvoseltamabFinal2026
L01FF16sasanlimab01.09.20252026
L01FF15envafolimabFinal2026
L01FF14camrelizumabFinal2026
L01EX29vimseltinibFinal2026
L01EP03 savolitinibFinal2026
L01EM06inavolisib01.09.20252026
L01EK05rivoceranibFinal2026
L01EH06sevabertinib01.09.20252026
L01EH05mifanertinib01.09.20252026
L01EH04zongertinibFinal2026
L01EE06tunlametinibFinal2026
L01EC04tovorafenibFinal2026
L01EB12firmonertinibFinal2026
J07BP02 1)chikungunya, virus-like particles01.09.20252026
J07BP01 1) chikungunya, live attenuated01.09.20252026
J07BB55influenza and covid-19, RNA-based vaccineFinal2026
J06BD11libevitug01.09.20252026
J06BD10clesrovimab01.09.20252026
J01FA17nafithromycinFinal2026
J01DI55sulopenem and probenecid01.09.20252026
J01CG30sulbactam and durlobactam01.09.20252026
H01CB06paltusotine01.09.20252026
G03CA10estetrol01.09.20252026
G02CX07elinzanetantFinal2026
D11AA02sofpironium bromideFinal2026
D06BB13berdazimer sodiumFinal2026
D03AX17diperoxochloric acidFinal2026
C10BX24rosuvastatin, amlodipine and telmisartanFinal2026
C10BX23rosuvastatin, amlodipine and ramiprilFinal2026
C10BA16atorvastatin and fenofibrate01.09.20252026
C10BA15rosuvastatin, ezetimibe and fenofibrate01.09.20252026
C10BA14pitavastatin and fenofibrateFinal2026
C10AX19lerodalcibep01.09.20252026
C09DX09candesartan, amlodipine and indapamide01.09.20252026
C09BB14zofenopril and amlodipineFinal2026
C03EB03torasemide and potassium-sparing agentsFinal2026
C03DA54eplerenone and dapagliflozin01.09.20252026
C02KN02baxdrostat01.09.20252026
B06AX07mozafancogene autotemcelFinal2026
B06AX06lovotibeglogene autotemcelFinal2026
B06AC09donidalorsenFinal2026
B02BX12fitusiranFinal2026
B02BD18arvenacogene sanparvovecFinal2026
A16AX29doxecitine and doxribtimineFinal2026
A16AX28sepiapterinFinal2026
A16AX27apraglutideFinal2026
A16AX26glepaglutideFinal2026
A16AB29rebisufligene etisparvovec01.09.20252026
A16AB28verenafusp alfaFinal2026
A12CB04zinc orotateFinal2026
A10BD34metformin and enavogliflozin01.09.20252026
A10BD33pioglitazone and dapagliflozinFinal2026
A10BD32glimepiride and dapagliflozinFinal2026
A10BD31metformin, sitagliptin and dapagliflozinFinal2026
A10AE57insulin icodec and semaglutideFinal2026
A05BA11resmetiromFinal2026
A05AX08linerixibatFinal2026
A05AA06norucholic acidFinal2026
A02BC12zastaprazan01.09.20252026
1) New ATC 5th level to be included in the new ATC 4th level J07BP Chikungunya vaccines in the Index 2026. Temporary code J07BX07 chikungunya vaccines will be deleted.

Last updated: 2025-06-10